Literature DB >> 27650418

Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab.

Tomonori Tadokoro1, Eri Keshino1, Akitaka Makiyama1, Takakazu Sasaguri1, Koichi Ohshima1, Harutaka Katano1, Masahiro Mohri2.   

Abstract

Entities:  

Keywords:  adverse events; heart failure; immune checkpoint inhibitor; melanoma; myocarditis

Mesh：

Substances：

Year:  2016        PMID： 27650418     DOI： 10.1161/CIRCHEARTFAILURE.116.003514

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN： 1941-3289            Impact factor:   8.790


× No keyword cloud information.
  26 in total

Review 1.  Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.

Authors:  Rachel E O'Neill; Xuefang Cao
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

2.  Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity.

Authors:  Nicolas Martinez-Calle; Paula Rodriguez-Otero; Sara Villar; Luis Mejías; Ignacio Melero; Felipe Prosper; Patricia Marinello; Bruno Paiva; Miguel Idoate; Jesus San-Miguel
Journal:  Haematologica       Date:  2018-04-12       Impact factor: 9.941

3.  Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

Authors:  Syed S Mahmood; Michael G Fradley; Justine V Cohen; Anju Nohria; Kerry L Reynolds; Lucie M Heinzerling; Ryan J Sullivan; Rongras Damrongwatanasuk; Carol L Chen; Dipti Gupta; Michael C Kirchberger; Magid Awadalla; Malek Z O Hassan; Javid J Moslehi; Sachin P Shah; Sarju Ganatra; Paaladinesh Thavendiranathan; Donald P Lawrence; John D Groarke; Tomas G Neilan
Journal:  J Am Coll Cardiol       Date:  2018-03-19       Impact factor: 24.094

Review 4.  Cardiovascular Toxicities Associated with Cancer Immunotherapies.

Authors:  Daniel Y Wang; Gosife Donald Okoye; Thomas G Neilan; Douglas B Johnson; Javid J Moslehi
Journal:  Curr Cardiol Rep       Date:  2017-03       Impact factor: 2.931

Review 5.  Heart failure in cancer: role of checkpoint inhibitors.

Authors:  Murilo Delgobo; Stefan Frantz
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 6.  Beta-Adrenergic Signaling in Tumor Immunology and Immunotherapy.

Authors:  Wei Wang; Xuefang Cao
Journal:  Crit Rev Immunol       Date:  2019       Impact factor: 2.214

Review 7.  T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword.

Authors:  Karin H Simons; Alwin de Jong; J Wouter Jukema; Margreet R de Vries; Ramon Arens; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2019-06       Impact factor: 32.419

8.  Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis.

Authors:  Jiexuan Hu; Ruyue Tian; Yingjie Ma; Hongchao Zhen; Xiao Ma; Qiang Su; Bangwei Cao
Journal:  Front Oncol       Date:  2021-05-27       Impact factor: 6.244

Review 9.  Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects.

Authors:  Wenlu Zou; Jie Lu; Yan Hao
Journal:  J Inflamm Res       Date:  2021-07-08

Review 10.  Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases.

Authors:  Emma Matzen; Lars Erik Bartels; Brian Løgstrup; Stine Horskær; Christina Stilling; Frede Donskov
Journal:  Cardiooncology       Date:  2021-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.